GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » Shiller PE Ratio

IVERIC bio (IVERIC bio) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


IVERIC bio Shiller PE Ratio Historical Data

The historical data trend for IVERIC bio's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Shiller PE Ratio Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of IVERIC bio's Shiller PE Ratio

For the Biotechnology subindustry, IVERIC bio's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Shiller PE Ratio falls into.



IVERIC bio Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

IVERIC bio's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, IVERIC bio's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.53/127.3478*127.3478
=-0.530

Current CPI (Mar. 2023) = 127.3478.

IVERIC bio Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -0.394 98.518 -0.509
201309 -10.260 98.790 -13.226
201312 -0.650 98.326 -0.842
201403 -0.640 99.695 -0.818
201406 -2.190 100.560 -2.773
201409 0.250 100.428 0.317
201412 -1.060 99.070 -1.363
201503 0.190 99.621 0.243
201506 -1.080 100.684 -1.366
201509 -1.140 100.392 -1.446
201512 -1.020 99.792 -1.302
201603 -1.030 100.470 -1.306
201606 -0.850 101.688 -1.064
201609 -1.710 101.861 -2.138
201612 -1.860 101.863 -2.325
201703 -1.200 102.862 -1.486
201706 -0.620 103.349 -0.764
201709 5.250 104.136 6.420
201712 -0.260 104.011 -0.318
201803 -0.360 105.290 -0.435
201806 -0.370 106.317 -0.443
201809 -0.410 106.507 -0.490
201812 2.620 105.998 3.148
201903 -0.300 107.251 -0.356
201906 -0.350 108.070 -0.412
201909 -0.350 108.329 -0.411
201912 -0.390 108.420 -0.458
202003 -0.280 108.902 -0.327
202006 -0.320 108.767 -0.375
202009 -0.270 109.815 -0.313
202012 -0.270 109.897 -0.313
202103 -0.290 111.754 -0.330
202106 -0.320 114.631 -0.355
202109 -0.230 115.734 -0.253
202112 -0.290 117.630 -0.314
202203 -0.290 121.301 -0.304
202206 -0.410 125.017 -0.418
202209 -0.350 125.227 -0.356
202212 -0.470 125.222 -0.478
202303 -0.530 127.348 -0.530

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IVERIC bio  (NAS:ISEE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


IVERIC bio Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142